First Gene Therapy For an Inherited Disease Could Soon Be Approved by The FDAScienceAlertBy contrast, Luxturna, the Spark product, represents what is thought of as true gene therapy, in which a functional gene does the job of a defective one. About 1,… Continue reading
Dr. Choueiri on the Research With Immunotherapy in RCCOncLiveToni Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses research involving immu… Continue reading
FierceBiotech |
Revamped CAR–T could curb HIV levels without antiretroviral drugs
FierceBiotech Adding a synthetic CAR protein to T cells makes them better able to fight a specific target, such as cancer or HIV. CAR-T therapy involves extracting a patient’s T cells, re-engineering them in a lab to express specific CAR proteins and then injecting … |
MarketWatch |
Spark Therapeutics’ promising gene therapy for vision loss could cost $1 million
MarketWatch Spark Therapeutics’ gene therapy for an otherwise incurable rare eye disease, if approved, could be a major milestone for the disease itself as well as the field of gene therapy. The therapy, Luxturna, was recommended for approval by a Food and Drug … Spark Therapeutics Inc. (ONCE) Moves Lower on Volume Spike for October 13Equities.com Spark Therapeutics (NASDAQ:ONCE): BMO Capital Reconfirms “Outperform” Rating Today, Has a Target of $101/ShareWeeklyHub 19.91 % to Target, BMO Capital Reconfirms ‘Outperform’ Rating on Spark Therapeutics (NASDAQ:ONCE) Shares TodayFinance News Daily Weekly Register all 88 news articles » |